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ABSTRACT
A cellular assay has been developed to allow meas-
urement of the inhibitory activity of large numbers
of oligonucleotides at the protein level. The assay is
centred on an mRNA fusion transcript construct
comprising of a full-length reporter gene with a
target region of interest inserted into the 3¢-untrans-
lated region. Luciferase and ¯uorescent reporter
genes were used in the constructs. The insert can
be from multiple sources (uncharacterised ESTs,
partial or full-length genes, genes from alternate
species, etc.). Large numbers of oligonucleotides
were screened for antisense activity against a
number of such constructs bearing different report-
ers, in different cell lines and the inhibitory pro®les
obtained were compared with those observed
through screening the oligonucleotides against the
corresponding endogenous genes assayed at the
mRNA level. A high degree of similarity in the
pro®les was obtained indicating that the fusion
constructs are suitable surrogates for the endogen-
ous messages for characterisation of antisense oli-
gonucleotides (ASOs). Furthermore, the results
support the hypothesis that the secondary structure
of mRNAs are divided into domains, the nature of
which is determined by primary nucleotide
sequence. Oligonucleotides whose activity is
dependent on the local structure of their target
mRNAs (e.g. ASOs, short interfering RNAs) can be
characterised via such fusion RNA constructs.
INTRODUCTION
In post-genomic times pharmaceutical research often begins
with the identi®cation of a gene product which is dysfunc-
tional or mis-regulated in a disease or in an experimental
model of a disease. In cellular assays, protein over-expression
or knock-down of expression are two readily accessible
molecular biology techniques commonly used to link a
speci®c protein causally to a phenotype or pathway thought
to play a role in the disease. These assays are followed with
increasingly more detailed experiments in more sophisticated
models which may lead to the point where the protein is
`validated' as a molecular target, to a suf®cient extent to
proceed to the next step, the identi®cation and development of
small molecule inhibitors, some of which will serve as starting
points or leads for medicinal chemistry programmes (1±3).
Gene knock-down is one of the most powerful techniques for
validation of pharmaceutical targets and is also applicable on
the genomic scale.
In 1977, Paterson et al. (4) demonstrated for the ®rst time
that gene expression could be inhibited sequence speci®cally
using exogenously delivered nucleic acids. A new ®eld,
known as antisense, emerged and various experimental
methods using the same principle were developed. The most
robust of these exploits is the use of synthetically prepared,
chemically modi®ed, short oligonucleotides (5), delivered into
cells, often with the aid of delivery reagents. This ®eld has
continued to develop, with the introduction of the RNA
interference mechanism (RNAi) (6±9).
One of the most persistent problems with the antisense
technique is the wide variability in biological potency often
observed among a set of oligonucleotide reagents against a
given mRNA target. Some are very potent, but many reagents
are only weakly biologically active. This phenomenon is
reported for most types of mRNA-targeting (oligonucleotide)
reagents: DNA-like antisense oligonucleotides (ASOs) (10),
arti®cial ribozymes (11), short interfering RNAs (siRNAs)
(12) and RNA molecules expressed from transfected arti®cial
DNA vectors (13). Furthermore, examples of sudden jumps in
activity have been reported when the position of ASOs is
shifted relative to the target sequence, sometimes by only a
single nucleotide (14) or in the case of siRNAs by 3 nt (12). So
far, robust rules to predict whether a given oligonucleotide
will have a high inhibitory power have not been reported.
Thus, prior to initiation of detailed biological experiments
against a given gene, some type of screening process is
necessary for the identi®cation of effective ASOs. Several
reports show that such optimisation of the target sequence by
pre-screening leads to antisense reagents with much higher
potency than the initial, arbitrarily selected sequences (15,16).
While this may be an effective method to identify the best
reagent prior to beginning detailed biological investigations of
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single genes, this approach is, however, no longer practical to
identify new targets on the genomics scale. On the level of
hundreds and thousands of target genes, an ef®cient selection
process must be in place to reliably identify highly potent and
highly speci®c ASOs against each individual target gene.
Multiple factors, many of which are interdependent, in¯uence
the biological activity of oligonucleotides in cell culture and
in vivo (17). On the RNA target itself, this includes the folded
structure, the proximity of the ribosomal binding site (i.e. the
translational start site or the CAP site) and the degree of
protein binding. For the oligonucleotides, chemical modi®ca-
tion is an important element which in¯uences a number of
secondary factors including the nature of lipoplex formation,
cellular uptake, interactions with RNA-cleaving enzymes
(RNase H, RNase P, RISC), the secondary structure of the
oligonucleotide, its metabolic stability and even the type of
cell being targeted (18). All of these factors together are
in¯uenced by the primary sequence of the oligonucleotide and
therefore also by the sequence of the binding site on the target.
The nucleotide sequence not only in¯uences the interaction
with the target RNA, but also the af®nity for other sequence-
related RNAs and cellular factors through non-Watson±Crick
binding interactions.
A prerequisite for an ASO strand to be an effective inhibitor
is high af®nity duplex formation between target and the ASO.
Formation of this duplex should not be impeded by the target
self-structure (19±21) or RNA-binding molecules, such as
proteins (22) and the binding site should ideally be pre-
organised to allow duplex formation, resulting in fast associ-
ation and slow dissociation (23). Various methods of pre-
screening ASOs for biological potency are known. Several
cell-free screening methods using in vitro-transcribed RNAs
have been described. Some of these use synthetic oligodeox-
yribonucleotide (DNA) libraries and RNAse H (24±27) in an
in vitro translation screening (28, 29). Also, hybridisation of
mRNA to immobilised oligonucleotides on arrays has been
used (30). These approaches were designed to highlight those
ASOs which bind most strongly to the target mRNA, based on
the assumption that the strongest binders are likely to
represent the most potent inhibitors in cells. These methods
are in fact effective techniques for identifying potent
inhibitors of gene expression. They work very well in cases
where the opportunity exists to fully characterise an ASO
before initiation of more complex biological experiments.
However, such a rigorous and often tedious characterisation
is not possible in the case of experiments carried out on
hundreds or thousands of genes, i.e. at the genomics scale.
Theoretical approaches to predict `good' target regions for
ASOs using thermodynamic calculations have been reported
to offer better results than a completely random selection of
ASOs (31,32) but these often led to the identi®cation of
regions in which individual sequences within the region
demonstrated sharp variations between high and low bio-
logical activity (14). Evidently, the most reliable way to
identify the most potent, speci®c, ASO is to synthesise all
possible candidate ASOs against a target sequence and test
them in the cellular environment by monitoring their effect on
target protein levels. While the technology for this approach,
i.e. high-throughput oligonucleotide synthesis for preparation
of very large numbers of oligonucleotides, is available today,
the means to monitor target protein levels from large numbers
of transfections, preferably in real time, requires development
of suitable assays. Once an assay is established, a process
involving the synthesis of all possible candidate oligonucleo-
tides against a target sequence and their testing in the cellular
environment becomes feasible.
Furthermore, such methods will allow a head-to-head
comparison of the inhibitory properties of hundreds to
thousands of different oligonucleotide sequences in their
cellular environment. Consequently, the possibility exists to
search using, for example, statistical methods or neural
networks (33), for the presence of short nucleotide motifs,
which contribute not only to biological potency, but also to
many other properties of oligonucleotides. Eventually such
techniques may lead to methods which allow accurate
prediction of the inhibitory activity of any given oligonucleo-
tide for its target.
Unfolding and refolding studies of single RNA molecules
have revealed that, in contrast to the secondary structural
elements of proteins, those of RNA are independently stable
(34). There is strong evidence suggesting that the structure of
short RNA segments, for example, that targeted by an ASO, is
primarily constrained by local secondary structure and that
this has a direct impact on biological activity of the
oligonucleotide (35). Thus, when a segment of mRNA is
taken from its natural endogenous mRNA and inserted into
another mRNA, it should maintain the same fundamental
features of its original structure with respect to accessibility to
oligonucleotides and, therefore, ASOs complementary to a
sequence within the segment should demonstrate similar
binding af®nities, and therefore similar levels of antisense
activity, to both the wild-type mRNA and the corresponding
construct mRNA. This hypothesis formed the foundation for
the development of a generally applicable, automated, cell-
based, high-throughput assay of oligonucleotide activity. The
method makes use of plasmid constructs which leads to
transcription of a fusion mRNA, comprising the coding
sequence of a reporter gene. The principle of these gene
fusions was ®rst demonstrated during experiments carried out
on plants (36). A region of selected cDNA sequence repre-
senting a part of the target gene is inserted into the 3¢-
untranslated region (3¢-UTR). The insert may originate from a
full-length gene or a partial gene; it may be derived from
coding or UTRs, and it may be from uncharacterised genes
and also may even derive from a gene of another species. Each
construct tested makes use of the same promoter and produces
the same protein product with similar levels of expression.
Therefore, this approach compares very favourably to one in
which the insert is included as part of the coding region, from
which potentially toxic, or even incorrectly folded fusion
proteins result. Moreover, use of the 3¢-UTR as opposed to the
5¢-UTR for the location of the insert ensures that the reporter
expression is not adversely affected by inclusion of undesired
inadvertent upstream translation initiation. A modi®cation in
the 3¢-UTR of an mRNA might potentially modify the RNA
stability, since stability determinants often lie within this
region. However, in any correlation between a reporter fusion
mRNA versus an endogenous mRNA one would not expect a
change in the relative potency ranking across a set of ASOs.
Furthermore, using reporter genes of no physiological rele-
vance results in a de-coupling of possible biological effects
caused by inhibition of functional mRNA targets and helps
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ensure that changes in target (reporter) protein levels result
solely from the antisense mechanism.
Most types of ASOs used today act by speci®c hybridisation
to their target mRNA, followed by induction of mRNA rapid
degradation via a RNase H-dependent mechanism (37±39),
resulting in lowered levels of protein. The fusion construct
principle has been tested in this study with MOE-modi®ed
gapmer ASOs (40) which derive their biological activity from
RNase H-induced degradation of mRNA. The inhibitory
activity of a large number of oligonucleotides targeting a set of
fusion constructs was correlated with their antisense activity
against their natural wild-type targets to test the hypothesis
that indeed the local mRNA structure is retained when the
segment is present in different mRNAs: in the wild-type
sequence and as part of the 3¢-UTR of the reporter gene
mRNA.
MATERIALS AND METHODS
Oligonucleotide synthesis
Synthesis and puri®cation of 2¢-O-methoxyethyl phosphodie-
ster or phosphorothioate and unmodi®ed deoxyphosphor-
othioate oligonucleotides were performed using an automated
DNA synthesiser with phosphoramidite chemistry, as previ-
ously described (41). The chemical format of the oligonucleo-
tides was NsNsNs NsNsNs NsNsNs nsnsns nsnsns nsnsn
(Fig. 3) or npnpnp npnpNs NsNsNs NsNsNs Nsnpnp npnpn
(Figs 4±7) where N indicates DNA; n is a 2¢-O-methoxyethyl
ribose modi®cation; s and p are phosphorothioate and
phosphodiester linkages, respectively. The sequences used in
this study are listed in Supplementary Material.
Two unrelated control ASOs were used: CsCsTs TsAsCs
CsTsGs cstsas gscsts gsgsc (4535) and cct taCs CsTsGs
CsTsAs Gsct ggc (5596). Oligonucleotides were puri®ed by
HPLC. Quantity and purity were monitored by electrospray
mass spectrometry and capillary gel electrophoresis, respect-
ively.
Construction of reporter expression clones
The ®re¯y luciferase reporter-based vector pNAS-020 (Fig. 2
and Table 1) was constructed to contain a multiple cloning site
after the luciferase stop codon for inserting the appropriate
cDNAs or ESTs of interest. The minimal CMV promoter
containing seven repeats of the tetracycline operator was
included for inducible expression studies known as the tet-off
system (42). Plasmid pSFhCMVT7neo1 (F. Asselbergs,
unpublished results) served as the starting vector for con-
struction of vector pNAS-020. The vector experienced no
changes at the cloning site (EcoRV, EcoRI, BglII), the splicing
acceptor, splicing donor and poly adenylation sites of beta
globin, pBR ori, the ampicillin resistance marker and the
SV40 ori. Subsequent cloning steps resulting in further
intermediate plasmids and ®nally the vector pNAS-20 was
obtained after inserting the ®re¯y luciferase gene (pGL3
control vector; Promega) at the NcoI/XbaI site.
The enhanced yellow ¯uorescent protein (eYFP) reporter-
based vector pNAS-055 (Fig. 2 and Table 1) was constructed
to contain a multiple cloning site after the stop codon of the
eYFP for inserting the cDNAs. pNAS-055 was generated
by inserting the BamHI/NotI fragment derived from the
peYFP-N1 vector (Clontech) into the BamHI/NotI site of
pcDNA/TO (Invitrogen) bearing the tet-operator.
The enhanced cyan ¯uorescent protein (eCFP) and eYFP
dual reporter-based vector pNAS-092 (Fig. 2 and Table 1) was
constructed to contain a multiple cloning site after the stop
codon of the eYFP for inserting the cDNAs. The eCFP
reporter serves for normalisation measurements driven under
the elongation factor 1 alpha (EF-1a) promoter and the eYFP
reporter was used to monitor antisense activity of ASOs driven
under the CMV promoter. The origin of the vector was a
plasmid pBudCE4 (Invitrogen) which contains a hCMV and a
EF-1a promoter. pNAS-092 was generated by inserting the
eCFP gene derived from peCFP-N1 (Clontech) at the depicted
restriction sites and by transferring the eYFP gene from
pNAS-055 together with a synthetic DNA fragment bearing
the cloning site (EcoRV, NotI, HindIII, KpnI, XbaI). All used
synthetic DNAs (for pNAS-020 and pNAS-092) were con-
®rmed by sequencing. All plasmids used for the ®nal reporter
assay were constructed by inserting into the cloning site the
c-DNA fragment of the EST clone, respectively. The synthetic
DNA sequences and the clone ID number of the used source
plasmids are listed in Supplementary Material.
Cell lines and cell culture
The Chinese hamster ovary (CHO) cell line SSF-3 was derived
from the dihydrofolate reductase (dhfr)-de®cient CHO line
DUKXB11. It can be grown in a basal medium completely
devoid of proteins (43). A recombinant line of SSF-3 bearing
the tetracycline responsive transactivator protein (tTA) and
the mutant hamster dhfr as selection marker (methotrexate
resistance) was used. tTA is compatible with the reporter
vector pNAS-020 for constitutive luciferase expression. SSF-3
cells were grown as adherent cells in 4-(2-hydroxyethyl)-
piperazine-1-ethane-sulfonic acid (HEPES) buffered Cho-
master medium (Messi Cell Culture Technology, ZuÈrich,
Switzerland) containing 10% bovine calf serum (BCS) (Life
Technologies) in a 5% humidi®ed CO2 atmosphere at 37°C.
Stable cells expressing the red-shifted enhanced green
¯uorescent protein [pd2eGFP-N1 (Clontech) Lipofectamine-
Plus transfection according to the manufacturer (Life
Technologies)] were selected as neo+ clones by the addition
of 1 mg/ml geneticin and further designated as SSF-3-G.
eGFP-expressing cells were used for accurate measurement
of cell numbers. This allows monitoring of each physical
manipulation of the cells during the different medium
replacement steps in the assay, and, in addition, the ¯uorescent
measurement serves for the normalisation of the luciferase
activity value per cell number equivalent.
The African green monkey kidney cell line COS-1 (CRL
1650) and the human non-small cell lung carcinoma cell line
H-1299 (CRL-5803) were purchased from ATCC (Rockville,
MD). COS-1 cells were grown in DMEM (Life Technologies)
containing 10% serum fetal bovine serum (FBS) (Life
Technologies). The H-1299 cell line was maintained in a 5%
humidi®ed CO2 atmosphere at 37°C in RPMI 1640 medium
(Life Technologies) containing 10% FBS. Stable cells of
H-1299 expressing the eCFP and the tetracyline repressor
(TR) protein [peCFP-N1 (Clontech), pcDNA6/TR
(Invitrogen); Lipofectamine-Plus co-transfection according
to the manufacturer (Life Technologies)] were selected as
neo+ clones by the addition of 1 mg/ml geneticin and further
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designated as H-1299-C-TR. The purpose for using eCFP-
expressing cells was a practical measurement of the cell
number which serves for the normalisation of the eYFP
activity value per cell. TR is compatible with the reporter
vector pNAS-055 for constitutive eYFP expression by adding
1 mg/ml tetracycline.
Luciferase reporter assays
SSF-3-G cells were split 48 h prior to transfection, reaching an
80% subcon¯uent stage. Cells were trypsinised, washed and
resuspended in OptiMEM-I (Life Technologies) and trans-
fected with plasmids directly afterwards in polypropylene
tubes and distributed in Costar 96-well assay plates (white,
clear bottom) using Lipofectamine-Plus reagent (®nal con-
centration: 1 ng/ml plasmid, 2 ml/ml Lipofectamine). After 2 h,
oligonucleotides were added in the presence of Lipofectin
(4 mg/ml/100 nM oligonucleotide) which was then further
incubated for 2 h. The medium was removed and replaced
with 100 ml of standard Cho-master medium containing 10%
BCS and incubated overnight at 37°C. eGFP expression,
serving as the cell number equivalent, was measured (an
excitation ®lter of 485/15 nm and an emission ®lter of
510/10 nm on a Victor2Ô; Berthold Technologies) after 22 h.
The medium was aspirated and cells treated with 50 ml of
passive lysis buffer (Promega). Luminescence was measured
immediately [in relative light units (RLU)] after a 100 ml
luciferase substrate (Promega) injection. The quotient RLU/
eGFP ¯uorescence counts express the luciferase activity per
cell number equivalent. The cell number versus ¯uorescence
intensity for the experiments described here was in the linear
range. For the correlation between the luciferase reporter
assay and the quantitative real-time reverse transcription PCR
(q-PCR) assay all oligonucleotide treatments were done in
triplicate. The luciferase mismatch control sequence 4535 was
set as 100%. The relative standard deviations were calculated
from the means of at least three independent oligonucleotide
treatments and found to be on average 13.3% (Fig. 3).
Fluorescent protein reporter assays (intercellular
normalisation)
H-1299-C-TR cells were transfected with a similar procedure
using culture medium containing 1 mg/ml tetracycline and the
cells were seeded in black 96-well assay plates (Costar, clear
bottom). Fluorescence was measured at 24 h intervals for 3
days. The ¯uorescence of eCFP and eYFP was measured with
an excitation ®lter of 436/20 nm and an emission ®lter of 480/
30 nm and an excitation ®lter of 500/25 nm and an emission
®lter of 535/30 nm, respectively. The quotient of eYFP/eCFP
¯uorescence counts expresses the eYFP activity per cell
number equivalent. For the correlation between the eYFP
reporter assay and the luciferase reporter assay all oligonu-
cleotide treatments were done in triplicate. The mean values
are presented as percent of unrelated control 5596. The
standard deviations from the mean of at least three independ-
ent oligonucleotide treatments were calculated and found to be
on average 15.8% and for the luciferase reporter assay 15.3%
(Fig. 4). The average of mismatch control sequences was set as
100% in Figure 5. The error bars represent the standard
deviation from the mean of at least three independent
oligonucleotide treatments.
Fluorescent protein assays with dual reporter construct
carrying a reference gene (intracellular normalisation)
COS-1 cells were transfected with a similar procedure in black
96-well assay plates using the Fugene (Roche Molecular
Biochemicals) reagent for plasmid transfection (®nal concen-
tration: 1 ng/ml plasmid, 2 ml/ml Fugene). After removing the
transfection mix, the medium without phenol red was added
and incubated for 3 days. All read-outs were measured as
described in section Fluorescent protein reporter assays
(intercellular normalisation). The quotient of eYFP/eCFP
¯uorescence counts expresses the relative eYFP activity of
transfected cells. The results are presented as percent of
unrelated control 5596 in Figure 6. Error bars represent the
standard deviation from the mean of three independent
oligonucleotide treatments. An optimised procedure was
established to achieve a relative standard derivation of
<13% in the 96-well assay format which allows a single
well screening mode to identify highly active oligonucleotides
(Fig. 7A and B). A improvement was observed when the cell
suspension was carefully and equally dispensed (50 ml) into
96-well assay plates before adding the plasmid Fugene
mixture to the cells. In addition, the ®nal concentration of
Lipofectin was 1.5 mg/ml/100 nM oligonucleotide and the
oligonucleotides were pre-diluted to 1.8 mM in 0.05 mM
HEPES buffer at pH 6.5.
mRNA analysis with q-PCR
H-1299 cells were plated in 6-well assay plates 1 day prior to
the transfection.
Oligonucleotide was added in the presence of Lipofectin
reagent (®nal concentration: 1.5 mg/ml/100 nM oligonucleo-
tide) for 4 h. The OptiMEM I lipoplex mix was removed,
replaced with fresh medium and incubated overnight. Total
RNA was extracted using the RNeasy 96 kit (Qiagen) and
quanti®ed ¯uormetrically with ribogreen (Molecular Probes).
For quantitative mRNA analysis, the TaqMan technology with
the q-PCR was performed on the ABI PRISM 7700 (Applied
Biosystems) according to the manufacturer's instructions for
one-tube q-PCR.
The relative quantitation of gene expression was calculated
as described in the ABI PRISM 7700 user bulletin no. 2
(Applied Biosystems). Each oligonucleotide was analysed in
at least two independent assays with duplicate samples. The q-
PCR was run in triplicate. The results are presented as percent
of unrelated control sequence 4535. Samples with a standard
deviation from the mean >25% were excluded in Figure 3.
RESULTS
Reporter gene constructs for mRNA fusion transcripts
and measurement of ASO activity
A reporter gene system for a cell-based screening of ASO
activity has been developed. The assay is based upon a series
of gene cassettes in which a cDNA segment is inserted such
that it becomes part of the 3¢-UTR of the expressed reporter
gene (Fig. 1A). The reporter protein expressed is identical for
each fusion RNA independent of the size of the insert
(Fig. 1B), although plasmids bearing different inserts yield
mRNAs which may exhibit different expression levels of the
reporter gene. The plasmid expressing the fusion mRNA and
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ASOs complementary to the cDNA insert, which bears all of
its own local structural elements, are sequentially transfected
into cells. The activity of the ASOs is scored as the degree of
inhibition of the expression of the reporter protein, either
luciferase or ¯uorescent protein (Fig. 1C).
Different reporter plasmids
Plasmids expressing different reporter proteins with multiple
cloning sites suitable for inserting any cDNA after the stop
codon were constructed. The plasmid maps are shown in
Figure 2 and the applications of these constructs are summar-
ised in Table 1.
Validation of the use of the reporter assay
A series of transfection experiments using eight luciferase
reporter fusion RNAs were performed. The set of eight
plasmids was constructed containing cDNA inserts of differ-
ent lengths derived from eight human genes all expressed in a
human non-small lung cancer (H-1299) cell line. For each
plasmid, a series of 5±10 ASOs spread across the length of
each insert region were designed and synthesised. The ASOs
had a GC content between 28 and 72% (average of 51%). A
BLAST search (GenBank) was performed against the whole
genome to ensure that the oligonucleotides had full comple-
mentarity to the target and no signi®cant cross-matching to
other sequences. Only ASOs containing more than two
mismatches against a cross target were selected. ASOs were
deliberately not selected within 40±60 nt of fusion junctions,
i.e. in regions where differences in local mRNA structure
between the two RNAs might be expected. The reporter
Figure 1. Schematic drawing of the construction of a fusion mRNA and the
mechanism of action of an oligonucleotide targeting the fusion mRNA.
(A) A fusion mRNA is generated from a plasmid in which an EcoRI/NotI
cDNA fragment is inserted into the reporter gene. Thus, a target RNA
region is created in the 3¢-UTR of the mRNA encoding the reporter protein
(luciferase or ¯uorescent protein). (B) Two examples of reporter constructs
produced from endogenous mRNAs are shown. In example 1, a full-length
cDNA is cloned into the vector to produce the fusion mRNA, whereas in
example 2, only a part of a cDNA, e.g. EST, is cloned into the vector. Both
types of constructs have been used as target sequences. (C) The ASO binds
to the endogenous mRNA as well as to the fusion RNA in the same local
environment, leading to message degradation due to RNase H cleavage.
Figure 2. Detached map of the reporter plasmids pNAS-020, pNAS-055
and pNAS-092 (see also Table 1). The cloning site adjacent to the STOP
codon of the ®re¯y luciferase (pNAS-020) and the eYFP (pNAS-055 and
pNAS-092) for cDNA or EST inserts is illustrated in the separate box.
Amp, ampicillin selection marker; Zeo, Zeocin selection marker; CMVmin,
minimal human cytomegalovirus promoter; CMV, human cytomegalovirus
promoter; EF-1a, elongation factor 1 alpha promoter; T7-prom, bacterial T7
promoter; SplD-BG, splicing donor site of rabbit b-globin; SplA-GB,
splicing acceptor site of rabbit b-globin; pA-BG, polyadenylation site of
rabbit b-globin; pA-SV40, polyadenylation site of simian virus 40;
pA-BGH, polyadenylation site of bovine growth hormone; pBRori, origin of
replication of pBR322; SV40ori, SV40 origin of replication. StuI-XhoI-®ll,
NheI-HindIII-®ll, HindIII-BamHI-®ll, NotI-StuI-®ll, SmaI-NotI-®ll,
NotI-XhoI-®ll, ®lled in Klenow-blunted ligation sites used for vector
constructions.
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plasmids were transfected into a CHO cell line (SSF-3) stably
expressing eGFP. After 2 h, the relevant ASOs were
transfected into the cells complexed with Lipofectin reagent
(see Materials and Methods). After an incubation period of 2 h
for the ASO, the medium was changed and the cells were lysed
on the following day to quantitate luciferase activity. The
experiments were performed using the pNAS-020 construct
(Table 1) and the ratio activity/cell number was determined
using the luciferase/¯uorescence counts, respectively. Assays
were performed in triplicate in a 96-well format. The value
observed for the control ASO (4535) was set to 100%. The
ASOs were than tested for their inhibitory activity of the
endogenous mRNAs in H-1299 cells using q-PCR.
Transfection involved the same but separately prepared
Table 1. Reporter constructs used in the study
Reporter construct Reporter protein (fusion RNA) Read-out ratio Normalisation Cells
pNAS-020 Fire¯y luciferase Luminescense/¯uorescensea Cell number equivalent SSF-3-Gb
pNAS-055 Fluorescent proteinc Fluorescensed/¯uorescensee Cell number equivalent H-1299-C-TRf
pNAS-092 Fluorescent proteinc Fluorescensed/¯uorescensee Intracellular reference COS-1
aFilter: excitation, 485/15 nm; emission, 510/10 nm.
bStable expression of eGFPd2.
ceYFP.
dFilter: excitation, 500/25 nm; emission, 535/30 nm.
eFilter: excitation, 436/20 nm; emission, 480/30 nm.
fStable expression of eCFP.
Figure 3. Correlation plot comparing the effect of 58 transfected ASOs on
endogenous mRNA levels in human H-1299 cells and the effect on fusion
mRNA of interest expressing the reporter in SSF-3-G cells. A series of
eight targets were compared derived from ESTs. Correlation coef®cient
r2 = 0.73 (linear least-squares regression). Dashed lines indicate the 95%
con®dence level for the prediction. The circled area indicates the region of
highly active ASOs. (Triangles) Most potent hits in the reporter assay from
each target. (Grey circle) Second-best ASO in the reporter assay corres-
ponding to the grey triangle. The white triangle outside of the circled area
belongs to a target against which no better ASO was found in the q-PCR.
(Crosses) Three values outside the 95% con®dence level.
Figure 4. Correlation plot comparing the effect of 32 transfected ASOs on
eYFP reporter constructs (construct type pNAS-055) bearing the fusion
RNA of interest in human H-1299-C-TR cells versus the effect on luciferase
reporter constructs (construct type pNAS-020) bearing the fusion RNA of
interest in SSF-3-G cells. Two EST targets were compared. Correlation
coef®cient r2 = 0.75 (linear least-squares regression). Dashed lines show the
95% con®dence level for the prediction. The cross indicates one value out-
side the con®dence level.
Figure 5. Out of 20 ASOs, the four most potent were identi®ed in a ¯uores-
cent protein reporter screen using a derivative of pNAS-055. Subsequently,
these four ASOs and their corresponding mismatches (mm) were re-tested
at 400 nM concentration using either activity of the reporter construct in H-
1299-C-TR cells (activity measured 48 h after transfection) or in H-1299
cells, by measuring the expression level of the endogenous mRNA activity
assayed by q-PCR (RNA isolated 24 h after transfection). Pairwise correl-
ation was found between both RNA targets, the model fusion mRNA and
the endogenous mRNA. From a correlation plot of the various activities a
correlation coef®cient of r2 = 0.86 was calculated (linear least-squares
regression).
Figure 6. Dose±response effect of three transfected ASOs tested on reporter
construct type pNAS-092. COS-1 cells were transfected and the read-outs
after 72 h are shown; plasmid transfection using FugeneÔ reagent.
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ASO-lipoplex and incubation was for 4 h. After 16 h, total
RNA was isolated and analysed by q-PCR. The two inhibitory
activities for each of the 58 ASOs and the control ASO were
plotted and are shown in Figure 3. Approximately half of the
ASOs reduced mRNA to 10±30% of control values (circled
area in Fig. 3). Only a few of the ASOs yielded <50% of target
reduction. The most potent ASOs against the reporter
constructs from the eight series are depicted as triangles in
Figure 3. Two data points fall outside of the circled area
representing highly active ASOs, although one of them was
also the most potent ASO in a transfection experiment in
which the endogenous target mRNA was measured by q-PCR
analysis. One ASO, represented by the triangle shaded in grey,
was found not to be highly potent against its endogenous target
as measured by q-PCR, compared with its high activity against
the reporter fusion. However, for this target mRNA the second
most potent ASO against the luciferase fusion mRNA was
found to be the most potent one against the endogenous gene
(grey circle in Fig. 3).
The results show an excellent correlation (r2 = 0.73),
demonstrating that the rank-order potency of each ASO series
is similar for both the reporter RNA and the natural
endogenous mRNA counterpart.
Comparison of luciferase and ¯uorescent protein
reporter systems
`Fingerprint' pro®les were generated representing the inhibi-
tory activity of 32 ASOs targeting a luciferase reporter derived
from luciferase construct NAS-020 and the comparable eYFP
construct derived from NAS-055 (Table 1). A correlation
coef®cient of r2 = 0.75 (Fig. 4) was obtained. The two reporter
assays were performed in different cell lines, a non-human line
SSF-3-G and a human line H-1299-C. This result, therefore,
demonstrates that the two reporting systems yield comparable
results.
Match±mismatch pairs comparison
Mismatch oligonucleotides were selected as gene-speci®c
negative controls. In our experience, the lipoplex of an
inactive ASO is preferable as a negative control over the use of
transfection reagent alone, whereas a `silent' irrelevant
oligonucleotide sequence serves as a generic negative control.
As a general rule, four nucleotides at internal positions were
permutated, generating mismatch control oligonucleotides
very closely related to their fully matched counterparts, with
care to avoid introduction of motifs with 4 consecutively
identical nucleotides. Mismatches were chosen after consider-
ation of the nearest neighbour free energy coef®cients (http://
rna.chem.rochester.edu) by choosing the strongest disrupting
mismatch pairs. In 96% of the mismatch cases examined with
the reporter assay, inhibitory activity of <25% was observed.
None of the mismatches was found to be more active than the
fully matched ASO. Using one reporter construct derived from
a pNAS-055 vector in a representative experiment, the four
most potent matched ASOs were re-tested together with their
mismatch controls (Fig. 5) against the reporter transcript and
the endogenous mRNA in the same H-1299 cell line. The
results were compared and, once again, the most inhibitory
ASO in the reporter assay was also found to be the most potent
one against the endogenous gene. Mismatch oligonucleotides
in both assays were found to be considerably less active than
their matched counterparts in both assays. Mismatched and
potent matched ASOs characterised with such reporter
constructs subsequently proved to be highly inhibitory on
function level read-outs in biological follow-up experiments
(data not shown).
Dual reporter construct carrying a reference geneÐuse
in single well screens
The performance of the reporter assays could be systematic-
ally improved by normalisation for the ef®ciency of plasmid
transfection. In the dual reporter plasmid NAS-092, a second
¯uorescent protein, eCFP was introduced adjacent to the eYFP
(Fig. 2). eCFP expression thus serves as a means to normalise
for plasmid transfection ef®ciency, whereas the fusion mRNA
reporter (eYFP) bears the RNA target region of interest.
Experience gained over a large number of experiments
performed with this normalisation has shown that in transient
transfection assays this leads to a very high level of
reproducibility, similar to that level obtained in experiments
performed in a stable cell line. An example of a dose±response
titration in a non-human cell line (COS-1) using a match±
mismatch pair of oligonucleotides targeting this dual reporter
vector is shown in Figure 6. The vector was then used to
screen 70 ASOs in single wells of a 96-well plate. The results
of a typical experiment using two 96-well plates are shown in
Figure 7A and B. Each plate carries 40 matched ASOs and 30
corresponding 4 nt mismatch ASOs. The microtitre plate
oligonucleotides were transfected into cell lines previously
transfected with either a dual reporter construct bearing the
target insert (Fig. 7A) or one carrying an unrelated insert
Figure 7. Ninety six single well screening of match and mismatch ASO
pairs on reporter construct type pNAS-092 with COS-1 cells after 48 h of
ASO transfection (150 nM); plasmid transfection with Fugene. Match ASOs
are on the left side of the ®gure. Four nucleotide mismatch controls to the
®rst 30 ASOs are shown on the right side. From left to right, the ®rst
depicted mismatch sequences correspond to the ®rst match sequences, etc.
Grey bars represent the most potent oligonucleotides. The 100% of control
black bar from each plate represents the average of 26 untreated plasmid
wells with the indicated relative error bar of 12.7 and 6.3%, respectively.
(A) Treatment of the reporter bearing the fusion RNA of interest with
ASOs. (B) Treatment of a control plasmid of an unrelated RNA fusion with
ASOs.
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(Fig. 7B). The use of a relatively low dose of ASOs (150 nM)
ensured a wide dynamic range from which discrimination of
ASO potency can be accurately discerned. In each plate, 26
randomly distributed wells were used for plasmid transfected
controls in order to calculate standard deviations. The match±
mismatch changeover at oligonucleotide no. 40 is clearly
observable. The use of an unrelated target reporter provides an
additional control for the speci®city of the ASOs for their
target mRNAs (Fig. 7B). This type of control is useful to
assess the toxicity of ASOs, caused, for example, by non-
speci®c binding to proteins. For example, ASO no. 40 showed
a signi®cant level (~25%) of non-speci®c inhibition.
DISCUSSION
Oligonucleotides are powerful biological tools commonly
used to help determine the function of genes. The potency of
the oligonucleotide varies widely according to a large variety
of interdependent parameters most of which are determined by
the primary sequence of the oligonucleotide and the structure
around the complementary binding site on the mRNA.
The purpose of this study was to develop a cell-based
reporter assay suitable for measuring in high throughput the
inhibitory properties of a whole series of ASOs, complemen-
tary to sets of genes. In the ®rst instance, such an assay enables
a rapid identi®cation of the most potent oligonucleotide
against its target as a tool for biological experiments.
However, the assay also permits head-to-head comparisons
of the inhibitory properties of very large numbers of
oligonucleotide sequences under identical experimental con-
ditions. The analysis of such data sets using pattern searching
tools is expected to help reveal the role of primary sequence,
in particular sequence motifs, in the mechanism of gene
knock-down by antisense or other oligonucleotide reagents.
To build a general homogeneous cellular assay suitable for
mRNA targets from any origin, it was ®rst necessary to
develop a strategy to rapidly clone cDNA inserts from target
sequences into a suitable plasmid cassette, carrying a reporter
gene for which target protein levels could be monitored. To
validate the use of this assay, it was then necessary to
demonstrate that ASOs targeting the insert sequence would
show similar levels of inhibition of the reporter protein as for
the endogenous wild-type target.
All of the constructs developed for this study involved
insertion of target cDNAs, or parts of target cDNAs, into the
3¢-UTR of the reporter. When working with large numbers of
different cDNA inserts from multiple sources, this cloning
strategy offers signi®cant practical advantages over an inser-
tion into the 5¢-UTR, for example, as noted earlier.
Transcription of the plasmid results in different fusion
mRNAs of the reporter gene, all extended in the 3¢-UTR
region, but with a constant open reading frame and therefore
with expression of a common reporter protein. This approach
helps to render the assay general with respect to a homo-
geneous expression of a reporter protein for inserted targets
from any location on a given gene, from any species. A key
step in the plasmid design was the inclusion of attR1 and attR2
cloning sites in the most advanced version of the cassette.
These render the vector suitable as a destination vector in the
Gateway (Invitrogen) cloning system. Clones isolated from
cDNA libraries constructed in Gateway entry vectors can be
transferred in high throughput in a single reaction (recombina-
tion) with high ef®ciency.
A wide range of experiments were performed in order to
validate the concept of the reporter fusion mRNA as a
surrogate for the endogenous message. The relative rank-order
potencies of 58 oligonucleotides targeting eight pairs of fusion
reporter and endogenous mRNAs across their common
regions were compared (Fig. 3). With the exception of a
relatively short common domain region, the reporter and the
endogenous mRNA pairs shared no sequence homology; two
different cell lines from two different species were used to
screen the two RNAs with the ASOs (hamster and human,
respectively). The reporter assay requires two transfections, a
plasmid transfection, followed by oligonucleotide transfec-
tion, compared with a single ASO transfection required for a
test against endogenous mRNAs. Furthermore, inhibition of
gene expression was assayed at two different levels, the
endogenous mRNA at the mRNA level using q-PCR and the
reporter fusion at the functional level of the protein. In spite of
these differences, a very high correlation, r2 = 0.73, was
obtained. Furthermore, close analysis of the data revealed that
if samples of the q-PCR measurements which showed
relatively high standard deviations (>625%) from the mean
of at least three independent transfections were included, the
correlation dropped to r2 = 0.68, indicating that the noise of the
individual assay method probably limits the maximum
correlation of the two methods. The results proved conclu-
sively that the eight domains examined in this study exhibit
identical accessibility to multiple ASOs from their corres-
ponding groups. With such a strong correlation between the
methods, it is easily possible to select potent ASOs against an
endogenous mRNA using the reporter fusion as a surrogate
target, and thus the primary goal of the study was achieved.
The second generation of reporter constructs uses instead of
the luciferase enzyme the eYFP. The use of ¯uorescent
proteins as reporters offers some signi®cant advantages over
the luciferase/luciferin system. The assay read-out is ¯uores-
cence which enables non-invasive measurement of the cellular
state and thus assay conduction in real time. As antisense
mechanisms have an important kinetic element, that of mRNA
and protein half life, the technical ability to follow changes in
reporter protein in real time is highly advantageous. In
addition, there is no reagent cost associated with the read-out.
This construct was tested in a set of experiments in order to
determine whether the high correlation is a general phenom-
enon. A second set of transfections with four plasmids to
determine the correlation between the inhibitory potency of 32
ASOs targeting a constant domain embedded in the 3¢-UTRs
of two different reporters and two cDNA targets, one
luciferase and the other eYFP (Fig. 4), were carried out in
an analogous fashion to the initial experiments described for
the luciferase reporter/endogenous mRNA (Fig. 3). Once
again, assays were performed in different cell lines and in this
case at different time points: generation of a detectable
luciferase activity over noise becomes signi®cant as early as
24 h after transfection, whereas the signal from the eYFP is
best measured after 48 h. The longer incubation time did not
change the rank order of potency within the ASO series. In this
experiment (Fig. 4), a very high correlation was observed,
again showing that antisense activity within given domain
regions is insensitive to the structure of the surrounding
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sequence, therefore, suggesting that the local domain structure
is identical in the two messages.
The results of reporter assays performed on recombinant
gene constructs, endogenous genes, in various cell lines, and
even in various species, correlate highly as shown in Figures 3
and 4. This ®nding can be interpreted to indicate that the
folding is primarily determined by local target structure alone,
that the effects of RNA-binding proteins from different
species are very similar, or that these proteins have much
lower af®nities than the ASOs. Thus, our experiments con®rm
an assumption which underlies many published experimental
designs, where ASOs found to be active in one cell type are
used to inhibit the same gene in another cell type.
In order to draw meaningful conclusions from experiments
using oligonucleotides, it is imperative to include good quality
controls. Non-sequence-related effects from the use of
oligonucleotides are well documented in the literature
(44,45). Inverted, sense or scrambled ASO sequences have
no relation to the parent compound and thus cannot be
expected to have similar physiochemical properties. Thus,
they are inferior controls. The commonly accepted best type of
control is a closely related mismatch oligonucleotide. These
oligonucleotides comprise of an almost identical sequence to
that of the parent compound and therefore share most of the
physicochemical properties of the match oligonucleotide.
However, the permutation of a small number of nucleotides in
the parent sequence is suf®cient to ensure that it binds with
much lower af®nity to the complementary mRNA than the
parent match compound. In this way, biological effects
induced by the match oligonucleotide, but not by the
mismatch control, are considered to be due to speci®c target
gene inhibition. The 5¢ and 3¢ ends of the match and
mismatch oligonucleotides are held identical to minimise
any differences between match and mismatch in annealing
properties (14, 23) and in susceptibility to exonuclease-
derived degradation.
Typically, four bases in an 18mer match are permutated to
generate the mismatch control, and the molecular weight and
the base composition is maintained as closely as possible.
Residual activity can sometimes be observed as shown with
the corresponding mismatch of ASO no. 2 (Fig. 5), as one
might expect in cases where the parent match oligonucleotide
has a very high af®nity for the target mRNA (46). In no cases
were mismatches more active than their parent match
sequences. Occasionally, a particular oligonucleotide treat-
ment can lead to an increase in the induction of reporter
protein (Fig. 7A and B, mismatch no. 18) for which no obvious
explanation could be found.
The ®nal re®nement of the reporter assay was the
incorporation of a cDNA coding for a second ¯uorescent
protein, eCFP under the control of a EF1-alpha promoter. This
leads to simultaneous transcription of two ¯uorescent proteins
after transfection: eCFP and eYFP, which are measured in
parallel. This permits an effective normalisation for the
plasmid transfection ef®ciency and contributes to assay
robustness.
The secondary structure of an RNA is the major determin-
ant of its conformation and the ease by which it interacts with
other biomolecules, including proteins, polynucleotides and
also synthetic oligonucleotides. There are several lines of
strong experimental evidence that the `accessibility' of an
mRNA to binding and initiation of an antisense mechanism is
determined by the secondary structure and not by sequence
base composition alone (47 and references therein). This
secondary structure is generally assumed to be formed in local
domains, established as the RNA is transcribed, rather than
folding after transcription is complete. These hypotheses were
supported by the observations of Vickers et al. (48) during a
study of single synthetically prepared DNAs transcribed as
different locally structured RNAs of 44±54 nt in length
bearing a complementary binding site to an ASO. Relocating
the whole domain from the 3¢- to the 5¢-UTR of the luciferase
reporter message did not affect the rank-order potency of the
ASOs, showing that the accessibility of the binding site is
conserved in that domain and is independent from the
surrounding mRNA sequence. However, when the binding
site was moved to different positions within the domain, for
example, into a rigid hairpin structure, then the potency of the
oligonucleotide was adversely affected.
In the experiments described here, a large number of cDNA
inserts, originating from EST sequences, and present within
the sequence of a series of natural genes expressed in the H-
1299 cell line, were cloned into the 3¢-UTR of a series of
reporter genes. Sets of ASOs targeting these insert regions
were designed and characterised for their inhibitory antisense
activity, both against the endogenous genes in the H-1299 cell
line and against the reporter mRNAs in a non-human cell line.
A correlation plot of the inhibitory activity in both cell lines
revealed a very high correlation for the inhibitory activity over
a large number of examples and it may be concluded that the
secondary structure of the target segments is highly similar in
both the endogenous message and also the reporter fusion. In
turn, the results of the experiment strongly imply that the
segments share an unaltered structure whether embedded
within their natural endogenous mRNAs or within the 3¢-UTR
of an unrelated mRNA.
These observations are in line with the view that mRNA
folding indeed occurs in relatively independent domains
during transcription, as it is unlikely that similar structures of a
given segment, as measured by the biological activities of
large sets of ASOs, would result from a global minimum free
energy after mRNA synthesis is complete. Furthermore, the
results also imply that sequence-speci®c RNA-binding
proteins are also relatively unaffected by surrounding seg-
ments and that long range RNA±RNA interactions do not
unduly in¯uence the effects of local structural elements on
antisense activity.
Development of this assay has delivered the means to
screen very large numbers of oligonucleotides in a high-
throughput manner for inhibitory activity. Coupled with a
novel cloning strategy, the screening can be extended to
oligonucleotides against multiple genes. The assay ful®ls the
original requirement for an assay to rapidly identify the
optimal, i.e. the most potent and selective, oligonucleotides to
be used as tools for biological experiments. Combining this
type of assay with the high-throughput synthesis of oligonu-
cleotides, experiments can be designed to help discover the
most important factors which determine the biological
potency of oligonucleotides. This assay was developed using
ASOs, but it also can be used with oligonucleotides operating
via other types of mRNA degradation or alternative inhibitory
processes, e.g. siRNA. Finally, the development of methods to
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study the action of large numbers of oligonucleotides in
parallel, sets the scene for an eventual whole genome knock-
down using such reagents.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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